EUVIMEDEUVIMED entdecken
Crossref

REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC

D. I. Yudin, K. K. Laktionov, R. A. Zukov, I. L. Obraz, D. V. Perunov, M. M. Magamedova, F. V. Moiseenko, E. О. Elsakova, A. V. Sultanbaev, K. V. Menshikov, M. A. Zafirova, S. V. Gamayunov und 3 weitere

Meditsinskiy sovet = Medical Council · 01.01.2026 · (21) · 96-108

DOI: 10.21518/ms2025-508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 01.01.2026. Verfasst von D. I. Yudin und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atezolizumab, bevacizumab, and chemotherapy (ABCP) is a standard of care for advanced non-squamous NSCLC, including post-TKI patients with EGFR/ALK mutations. Real-world data on ABCP efficacy in Russia are limited.

Aim

To evaluate OS and PFS in real-world NSCLC patients who received ≥4 cycles of first-line ABCP followed by atezolizumab-bevacizumab (AB) maintenance. Materials and methods . REACT is an observational, retrospective, multicenter study of adult patients with advanced NSCLC (diagnosed 2021–2023) who received ≥4 ABCP cycles and started AB maintenance. Key endpoints included ORR, PFS, and OS.

Results

Data from 108 patients were included: 78 patients (72.2%) received ABCP in first line (wild type) and 30 (27.8%) were post-TKI (EGFR/ALK+). Median age 57.6 years; 63.9% male. Baseline metastases: CNS (17.6%), liver (8.3%), bone (33.3%). ORR was 56.5% (59.0% first line); DCR 98.2%. Median PFS was 14.7 months (95% CI 12.4–23.9) in first line group and 9.3 months (95% CI 7.4–14.6) in post-TKI group. Median OS was 34.4 months (95% CI 21.8–NR) in first line group and 24.2 months (95% CI 21.8–NR) post-TKI. 2-year OS rates were 52.7% and 54.4%, respectively. High tumor burden (≥3 sites), large sum of longest diameters, and bone metastases were negative prognostic factors. Age, sex, smoking, and PD-L1 status had no significant impact.

Conclusion

In this cohort, the ABCP regimen was highly effective. Results align with IMpower150 trial for post-TKI patients and demonstrate prolonged survival in the first-line setting.

Zitieren

APA

Yudin, D. I., Laktionov, K. K., Zukov, R. A., Obraz, I. L., Perunov, D. V., Magamedova, M. M., Moiseenko, F. V., Elsakova, E. О., Sultanbaev, A. V., Menshikov, K. V., Zafirova, M. A., Gamayunov, S. V., Abdelgafur, A. M., Petkau, V. V., & Moiseenko, V. M. (2026). REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC. Meditsinskiy sovet = Medical Council, 96-108. https://doi.org/10.21518/ms2025-508

Vancouver

Yudin DI, Laktionov KK, Zukov RA, Obraz IL, Perunov DV, Magamedova MM, et al. REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC. Meditsinskiy sovet = Medical Council. 2026:96-108. doi:10.21518/ms2025-508

BibTeX
@article{Yudin2026,
  author = {Yudin, D. I. and Laktionov, K. K. and Zukov, R. A. and Obraz, I. L. and Perunov, D. V. and Magamedova, M. M. and Moiseenko, F. V. and Elsakova, E. О. and Sultanbaev, A. V. and Menshikov, K. V. and Zafirova, M. A. and Gamayunov, S. V. and Abdelgafur, A. M. and Petkau, V. V. and Moiseenko, V. M.},
  title = {REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC},
  journal = {Meditsinskiy sovet = Medical Council},
  year = {2026},
  number = {21},
  pages = {96--108},
  doi = {10.21518/ms2025-508}
}
Kostenlos starten →